AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
pirtobrutinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| agammaglobulinaemia tyrosine kinase (Bruton tyrosine kinase) inhibitors | 5709 | 2101700-15-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK. BTK is a signaling protein of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Pirtobrutinib binds to wild type BTK and BTK harboring C481 mutations, leading to inhibition of BTK kinase activity. In nonclinical studies, pirtobrutinib inhibited BTK-mediated B-cell CD69 expression and inhibited malignant B-cell proliferation. Pirtobrutinib showed dose-dependent anti-tumor activities in BTK wild type and BTK C481S mutant mouse xenograft models.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.20 | g | O |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ALK,AURKA,AXL,BRAF,CAMK2B,CAMK2D,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,FLT3,GRK2,ITK,JAK1,KDR,LYN,MAP3K1,MAP3K10,MAP3K11,MAP3K21,MAP4K1,MAP4K3,MAPK10,MAPK7,MARK4,MET,NTRK1,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PRKCD,PRKDC,SIK2,SIK3,STK33,TGFBR1,TNIK,TTK,ULK1 | 48 | |||
| kinase-selectivity-class | AURKC,AXL,EIF2AK3,GRK2,PDK1,SIK2,SIK3 | 7 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 15.205 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 1 | |||
| rat-kpuu-brain | Rat brain Kpuu | 0.020 | % | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 27, 2023 | FDA | LOXO ONCOLOGY INC | |
| Oct. 30, 2023 | EMA | ELI LILLY NEDERLAND B.V. |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01EL05 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Bruton's tyrosine kinase (BTK) inhibitors |
| MeSH PA | D000092004 | Tyrosine Kinase Inhibitors |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D047428 | Protein Kinase Inhibitors |
| FDA EPC | N0000175605 | Kinase Inhibitor |
| FDA MoA | N0000182140 | Cytochrome P450 2C19 Inhibitors |
| FDA MoA | N0000185503 | P-Glycoprotein Inhibitors |
| FDA MoA | N0000187062 | Cytochrome P450 2C8 Inhibitors |
| FDA MoA | N0000190113 | Breast Cancer Resistance Protein Inhibitors |
| FDA MoA | N0000190114 | Cytochrome P450 3A Inhibitors |
| FDA MoA | N0000193934 | Brutons Tyrosine Kinase Inhibitors |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35705 | immunosuppressive agent |
| CHEBI has role | CHEBI:68495 | apoptosis inducer |
| CHEBI has role | CHEBI:76617 | EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor |
Related Drugs by ATC class:
L01EL Bruton's tyrosine kinase (BTK) inhibitors 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Relapsed or refractory mantle cell lymphoma (MCL) | indication | 443487006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 100MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | 10464905 | Dec. 16, 2036 | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE PREVIOUSLY BEEN TREATED WITH A COVALENT BTK INHIBITOR |
| 100MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | 10464905 | Dec. 16, 2036 | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR |
| 100MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | 10695323 | Dec. 16, 2036 | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE PREVIOUSLY BEEN TREATED WITH A COVALENT BTK INHIBITOR |
| 100MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | 10695323 | Dec. 16, 2036 | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR |
| 100MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | 10918622 | Dec. 16, 2036 | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE PREVIOUSLY BEEN TREATED WITH A COVALENT BTK INHIBITOR |
| 100MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | 10918622 | Dec. 16, 2036 | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR |
| 100MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | 12220401 | Dec. 16, 2036 | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE PREVIOUSLY BEEN TREATED WITH A COVALENT BTK INHIBITOR |
| 100MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | 12220401 | Dec. 16, 2036 | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR |
| 50MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | 10464905 | Dec. 16, 2036 | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE PREVIOUSLY BEEN TREATED WITH A COVALENT BTK INHIBITOR |
| 50MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | 10464905 | Dec. 16, 2036 | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR |
| 50MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | 10695323 | Dec. 16, 2036 | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE PREVIOUSLY BEEN TREATED WITH A COVALENT BTK INHIBITOR |
| 50MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | 10695323 | Dec. 16, 2036 | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR |
| 50MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | 10918622 | Dec. 16, 2036 | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE PREVIOUSLY BEEN TREATED WITH A COVALENT BTK INHIBITOR |
| 50MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | 10918622 | Dec. 16, 2036 | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR |
| 50MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | 12220401 | Dec. 16, 2036 | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE PREVIOUSLY BEEN TREATED WITH A COVALENT BTK INHIBITOR |
| 50MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | 12220401 | Dec. 16, 2036 | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 100MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | Jan. 27, 2028 | NEW CHEMICAL ENTITY |
| 50MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | Jan. 27, 2028 | NEW CHEMICAL ENTITY |
| 100MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | Dec. 2, 2028 | EXPANSION TO THE TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) INDICATION |
| 50MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | Dec. 2, 2028 | EXPANSION TO THE TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) INDICATION |
| 100MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | Jan. 27, 2030 | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR |
| 50MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | Jan. 27, 2030 | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR |
| 100MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | Dec. 1, 2030 | TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE RECEIVED AT LEAST TWO PRIOR LINES OF THERAPY, INCLUDING A BTK INHIBITOR AND A BCL-2 INHIBITOR |
| 50MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | Dec. 1, 2030 | TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE RECEIVED AT LEAST TWO PRIOR LINES OF THERAPY, INCLUDING A BTK INHIBITOR AND A BCL-2 INHIBITOR |
| 100MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | Dec. 3, 2032 | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE PREVIOUSLY BEEN TREATED WITH A COVALENT BTK INHIBITOR, EXCLUDING PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR LINES OF THERAPY, INCLUDING A BTK INHIBITOR AND A BCL-2 INHIBITOR |
| 50MG | JAYPIRCA | LOXO ONCOL | N216059 | Jan. 27, 2023 | RX | TABLET | ORAL | Dec. 3, 2032 | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE PREVIOUSLY BEEN TREATED WITH A COVALENT BTK INHIBITOR, EXCLUDING PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR LINES OF THERAPY, INCLUDING A BTK INHIBITOR AND A BCL-2 INHIBITOR |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Tyrosine-protein kinase BTK | Kinase | INHIBITOR | IC50 | 8.50 | DRUG LABEL | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| CHEBI:229212 | CHEBI |
| Y7W | PDB_CHEM_ID |
| CHEMBL4650485 | ChEMBL_ID |
| C000723100 | MESH_SUPPLEMENTAL_RECORD_UI |
| 11628 | IUPHAR_LIGAND_ID |
| 1351539006 | SNOMEDCT_US |
| 4042010 | VANDF |
| C5554559 | UMLSCUI |
| 11681 | INN_ID |
| 129269915 | PUBCHEM_CID |
| 364958 | MMSL |
| 41212 | MMSL |
| d09984 | MMSL |
| 019282 | NDDF |
| D12050 | KEGG_DRUG |
| JNA39I7ZVB | UNII |
| 2629338 | RXNORM |
| JNA39I7ZVB | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| JAYPIRCA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0002-6902 | TABLET, COATED | 50 mg | ORAL | NDA | 30 sections |
| JAYPIRCA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0002-7026 | TABLET, COATED | 100 mg | ORAL | NDA | 30 sections |